ScholarIQanswers from OpenAlex
Neuroendocrine Tumor Research Advances
TopicLeading institutions, researchers & key papers
Neuroendocrine Tumor Research Advances is a topic indexed in ScholarIQ from OpenAlex.
What is known about Neuroendocrine Tumor Research Advances?
ScholarIQrecord summary
This cluster of papers focuses on the epidemiology, classification, management, and treatment of neuroendocrine tumors, with a specific emphasis on pancreatic neuroendocrine tumors. It covers topics such as somatostatin receptor-based imaging and therapy, MEN1 syndrome, peptide receptor radionuclide therapy, genetic mutations associated with these tumors, and survival analysis.
How many works does Neuroendocrine Tumor Research Advances have?
ScholarIQindexed works
Neuroendocrine Tumor Research Advances has 550 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.
What is the OpenAlex record for Neuroendocrine Tumor Research Advances?
ScholarIQopenalex
The OpenAlex for Neuroendocrine Tumor Research Advances is on the source record.
What are the most-cited papers on Neuroendocrine Tumor Research Advances?
ScholarIQmost cited works
One Hundred Years After “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States
James C. Yao, Manal M. Hassan, Alexandria T. Phan, Cecile G. Dagohoy, Colleen Leary, Jeannette E. Mares, Eddie K. Abdalla, Jason B. Fleming, Jean‐Nicolas Vauthey, Asif Rashid, Douglas B. Evans
Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States
Arvind Dasari, Chan Shen, Daniel M. Halperin, Bo Zhao, Shouhao Zhou, Ying Xu, Ya‐Chen Tina Shih, James C. Yao
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
Jonathan Strosberg, Ghassan El‐Haddad, Edward M. Wolin, Andrew Hendifar, James C. Yao, Beth Chasen, Erik Mittra, Pamela L. Kunz, Matthew H. Kulke, Heather A. Jacene, David Bushnell, Thomas M. O’Dorisio, Richard P. Baum, Harshad Kulkarni, Martyn Caplin, Rachida Lebtahi, Timothy J. Hobday, Ebrahim S. Delpassand, Eric Van Cutsem, Al B. Benson, Rajaventhan Srirajaskanthan, Marianne Pavel, Jaime Font de Mora, Jordan Berlin, Enrique Grande, Nicholas S. Reed, Ettore Seregni, Kjell Öberg, Maribel Lopera Sierra, Paola Santoro, Thomas Thevenet, Jack L. Erion, Philippe Ruszniewski, Dik J. Kwekkeboom, Eric P. Krenning
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
James C. Yao, Manisha H. Shah, Tetsuhide Ito, C. Lombard Bohas, Edward M. Wolin, Eric Van Cutsem, Timothy J. Hobday, Takuji Okusaka, Jaume Capdevila, Elisabeth G.E. de Vries, Paola Tomassetti, Marianne Pavel, Sakina Hoosen, T Haas, Jeremie Lincy, David Lebwohl, Kjell Öberg
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors
Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul, Yung‐Jue Bang, Ivan Borbath, Catherine Lombard‐Bohas, Juan W. Valle, Peter Metrakos, Denis Smith, Aaron I. Vinik, Jen‐Shi Chen, Dieter Hörsch, Pascal Hammel, Bertram Wiedenmann, Eric Van Cutsem, Shem Patyna, Dongrui R. Lu, C. Blanckmeister, Richard C. Chao, Philippe Ruszniewski
Where is Neuroendocrine Tumor Research Advances research published, and who funds it?
ScholarIQvenues & funding sources
TOP JOURNALS
TOP FUNDERS
National Science Foundation—
NIH—
Wellcome Trust—
European Research Council—
Funder breakdown is a member featureSign up free to unlock
How much of the research on Neuroendocrine Tumor Research Advances is open access?
ScholarIQopen access share
53%OPEN ACCESS